Skip to main content

and
  1. No Access

    Article

    Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer

    Despite the development of novel effective therapeutic strategies, metastatic castration-resistant prostate cancer (mCRPC) remains a disease with a lethal course and a high biological and molecular heterogenei...

    Alessandra Modena, Roberto Iacovelli, Aldo Scarpa, Matteo Brunelli in Targeted Oncology (2016)

  2. No Access

    Article

    Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?

    Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. ...

    Alessandra Modena, Francesco Massari, Chiara Ciccarese in Targeted Oncology (2016)

  3. No Access

    Article

    The route to personalized medicine in bladder cancer: where do we stand?

    Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target...

    Francesco Massari, Chiara Ciccarese, Matteo Santoni, Matteo Brunelli in Targeted Oncology (2015)